BioMérieux: exceeds growth target in 2017
(CercleFinance.com) - BioMérieux has published 2017 turnover of 2,288 million euros, up 10.
2% like-for-like, slightly exceeding the group's target of between 9% and 10%, with published growth of 8.8%.
This growth has been boosted by all of the group's strategic lines, and particularly by the Biofire Filmarray range. The group points out an acceleration in the EMEA and Asia-Pacific regions, while America is continuing with double-digit growth.
Benefiting from this dynamic business, the in vitro diagnosis specialist anticipates contributory underlying operating income to be in line with the target previously set of between 330 million and 345 million euros.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
2% like-for-like, slightly exceeding the group's target of between 9% and 10%, with published growth of 8.8%.
This growth has been boosted by all of the group's strategic lines, and particularly by the Biofire Filmarray range. The group points out an acceleration in the EMEA and Asia-Pacific regions, while America is continuing with double-digit growth.
Benefiting from this dynamic business, the in vitro diagnosis specialist anticipates contributory underlying operating income to be in line with the target previously set of between 330 million and 345 million euros.
Copyright (c) 2018 CercleFinance.com. All rights reserved.